Key Points
- Insider selling: Director Barry Quart sold 2,690 shares on Feb. 12 at an average price of $45.00 for $121,050, leaving him with 12,546 shares (a 17.66% reduction).
- CFO Mark Ragosa also executed a large sale — 17,845 shares at about $43.28 (~$772k) — trimming his stake by roughly 59.6%, and multiple insider sales in days could amplify short-term selling pressure.
- Despite these sales, KNSA trades near its 52-week high (opened at $44.71) and benefits from analyst support (average target $52.33) and ~54% institutional ownership, indicating continued institutional confidence and potential upside.
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) Director Barry Quart sold 2,690 shares of the stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $45.00, for a total transaction of $121,050.00. Following the completion of the sale, the director owned 12,546 shares of the company's stock, valued at approximately $564,570. This represents a 17.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Kiniksa Pharmaceuticals International Stock Down 0.6%
Kiniksa Pharmaceuticals International stock opened at $44.71 on Friday. The company's 50 day moving average price is $42.14 and its two-hundred day moving average price is $38.72. The stock has a market cap of $3.39 billion, a P/E ratio of 99.36 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a 52 week low of $18.25 and a 52 week high of $45.50.
Kiniksa Pharmaceuticals International News Summary
Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:
- Positive Sentiment: Analyst support remains: several sell-side firms have recent buy/outperform ratings and raised targets (Citigroup, Wedbush, Goldman Sachs among them), keeping longer-term sentiment constructive and implying upside vs. current price. MarketBeat Coverage
- Positive Sentiment: Large institutional holders continue to own meaningful stakes (Rubric, Vanguard, Arrowstreet, Acadian, Qube), which can support share demand and reduce volatility from retail flows. Institutional Ownership Details
- Neutral Sentiment: Short-interest reporting appears to be a data glitch (entries show “0 shares” and NaN increases); there’s no clear evidence of a new short-squeeze or large new short positions impacting near-term flows. (Likely reporting error.)
- Neutral Sentiment: Technical/context: KNSA sits near its 52-week high and above its 50- and 200-day moving averages — bullish technically but also means some traders may take gains at these levels.
- Negative Sentiment: Significant insider selling: CFO Mark Ragosa sold 17,845 shares at an average $43.28 (≈$772k) and recently reduced his stake materially (~59.6% reduction). Large officer sales often trigger short-term selling pressure or investor concern about insider conviction. Ragosa SEC Form 4
- Negative Sentiment: Additional insider sells: Director Barry D. Quart sold ~2,690 shares on Feb 12 (and 110 shares Feb 10) at ~$45, trimming his holdings. Multiple insiders selling within days can amplify negative investor reaction. Quart SEC Form 4
Institutional Trading of Kiniksa Pharmaceuticals International
Several large investors have recently added to or reduced their stakes in KNSA. EverSource Wealth Advisors LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after purchasing an additional 532 shares in the last quarter. Osaic Holdings Inc. bought a new position in Kiniksa Pharmaceuticals International during the 2nd quarter valued at approximately $31,000. USA Financial Formulas purchased a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter worth about $32,000. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter worth approximately $41,000. Finally, CIBC Private Wealth Group LLC purchased a new stake in Kiniksa Pharmaceuticals International during the 4th quarter valued at $41,000. Institutional investors own 53.95% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts have issued reports on the company. Wedbush raised their target price on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an "outperform" rating in a research report on Tuesday, January 13th. Weiss Ratings reissued a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a report on Sunday, November 2nd. Citigroup increased their target price on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Friday, October 17th. Finally, Zacks Research cut shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "strong sell" rating in a research report on Tuesday, January 13th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $52.33.
Get Our Latest Research Report on Kiniksa Pharmaceuticals International
About Kiniksa Pharmaceuticals International
(
Get Free Report)
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
